Sanofi (SAN:CA) Q2 2026 Earnings Call Transcript

SA Transcripts 161.35K Followers Follow Sanofi ( SAN:CA ) Q2 2026 Earnings Call July 30, 2026 7:00 AM EDT Company Participants Thomas Larsen - Head of Investor Relations & General Medicines Belen Garijo Lopez - CEO & Director François-Xavier Roger - Executive VP & CFO Mike Quigley Manuela Buxo - Executive VP & Head of Specialty Care Roy Papatheodorou - Executive VP & General Counsel Thomas Triomphe - Executive Vice President of Vaccines Conference Call Participants James Quigley - Goldman Sachs Group, Inc., Research Division Sachin Jain - BofA Securities, Research Division Peter Verdult - BNP Paribas, Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Simon Baker - Rothschild & Co Redburn, Research Division David Risinger - Leerink Partners LLC, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Michael Leuchten - Jefferies Financial Group Inc. Richard Vosser - JPMorgan Chase & Co, Research Division Matthew Weston - UBS Investment Bank, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division James Gordon - Barclays Bank PLC, Research Division Presentation Thomas Larsen Head of Investor Relations & General Medicines Hello, everyone. This is Thomas Larsen from the Sanofi IR team. Welcome to the Second Quarter 2026 Conference Call for investors and analysts. Slides can be found on sanofi.com. Please turn to Slide #3. Here are the forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risks and uncertainties that may cause actual results to differ materially. We encourage you to read the disclaimer in the presentation. We also refer you to our Form 20-F on file with the U.S. SEC and our French universal registration document. We're going to make comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in millions of euros and for the second quarter, unless we stated otherwise.